Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zim Biosciences is a private wound-healing and dermatology-focused biotech developing protein-polymer complexes designed to accelerate skin repair and create an instant natural skin barrier. Its lead technology is a water-soluble keratin-containing complex intended for topical use across radiation dermatitis, atopic dermatitis, rosacea, burns, surgical incisions, and other skin injuries. The company appears to operate as a platform-oriented early commercial business, with technology that can be incorporated into medical and over-the-counter skin products. Publicly available information suggests Zim is small and privately held, with active web presence and issued intellectual property around compositions for improving skin quality. The company is best understood as a specialized regenerative skin-repair company rather than a traditional drug developer with a disclosed clinical-stage therapeutic pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zim Biosciences.